Semin Thromb Hemost 2014; 40(05): 577-584
DOI: 10.1055/s-0034-1383826
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Platelet Membrane Glycoproteins: A Historical Review[*]

Alan T. Nurden
1   L'Institut de Rhythmologie et Modélisation Cardiaque (LIRYC), Plateforme Technologique et d'Innovation Biomédicale (PTIB), Hôpital Xavier Arnozan, Pessac, France
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
26. Juni 2014 (online)

Preview

Abstract

The search for the components of the platelet surface that mediate platelet adhesion and platelet aggregation began for earnest in the late 1960s when electron microscopy demonstrated the presence of a carbohydrate-rich, negatively charged outer coat that was called the “glycocalyx.” Progressively, electrophoretic procedures were developed that identified the major membrane glycoproteins (GP) that constitute this layer. Studies on inherited disorders of platelets then permitted the designation of the major effectors of platelet function. This began with the discovery in Paris that platelets of patients with Glanzmann thrombasthenia, an inherited disorder of platelet aggregation, lacked two major GP. Subsequent studies established the role for the GPIIb-IIIa complex (now known as integrin αIIbβ3) in binding fibrinogen and other adhesive proteins on activated platelets and the formation of the protein bridges that join platelets together in the platelet aggregate. This was quickly followed by the observation that platelets of patients with the Bernard–Soulier syndrome, with macrothrombocytopenia and a distinct disorder of platelet adhesion, lacked the carbohydrate-rich, negatively charged, GPIb. It was shown that GPIb, through its interaction with von Willebrand factor, mediated platelet attachment to injured sites in the vessel wall. What follows is a personal reflection on the studies that were performed in the early pioneering days.

* This article is dedicated to Professors Jacques Caen and Peter Castaldi. Jacques Caen is the father of studies on inherited disorders of platelets and gave me my chance during my early years in Paris. His knowledge and drive meant that he was always pushing back the boundaries of knowledge. Peter Castaldi was one of the early pioneers of studies on Glanzmann thrombasthenia and provided much encouragement to me during my early years in Paris. I wish them both a long and happy retirement.